AC Immune Ltd (ACIU) - Cash Flow Conversion Efficiency
Based on the latest financial reports, AC Immune Ltd (ACIU) has a cash flow conversion efficiency ratio of -0.366x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-16.45 Million) by net assets ($44.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See ACIU defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
AC Immune Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)
This chart illustrates how AC Immune Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
AC Immune Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of AC Immune Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Acadian Timber Corp
TO:ADN
|
0.001x |
|
Backblaze Inc
NASDAQ:BLZE
|
0.069x |
|
Metro Mining Limited
F:6ME
|
-0.025x |
|
First Savings Financial Group Inc
NASDAQ:FSFG
|
0.544x |
|
Rishabh Instruments Limited
NSE:RISHABH
|
0.045x |
|
XANO Industri AB (publ)
ST:XANO-B
|
-0.008x |
|
BAIRONG INC.CL.B -00002
F:6B5
|
N/A |
|
ADAGENE INC. SP.ADR
F:978
|
N/A |
Annual Cash Flow Conversion Efficiency for AC Immune Ltd (2013–2025)
The table below shows the annual cash flow conversion efficiency of AC Immune Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of AC Immune Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $44.93 Million | $-66.15 Million | -1.472x | -351.01% |
| 2024-12-31 | $112.27 Million | $65.84 Million | 0.586x | +255.96% |
| 2023-12-31 | $160.64 Million | $-60.41 Million | -0.376x | +13.62% |
| 2022-12-31 | $168.99 Million | $-73.57 Million | -0.435x | -53.74% |
| 2021-12-31 | $231.98 Million | $-65.69 Million | -0.283x | -2.52% |
| 2020-12-31 | $215.48 Million | $-59.52 Million | -0.276x | -236.27% |
| 2019-12-31 | $272.44 Million | $55.22 Million | 0.203x | +181.68% |
| 2018-12-31 | $177.62 Million | $-44.08 Million | -0.248x | -31.23% |
| 2017-12-31 | $116.84 Million | $-22.09 Million | -0.189x | -376.86% |
| 2016-12-31 | $142.38 Million | $-5.65 Million | -0.040x | -106.39% |
| 2015-12-31 | $71.04 Million | $44.08 Million | 0.621x | +182.63% |
| 2014-12-31 | $23.47 Million | $-17.62 Million | -0.751x | +81.57% |
| 2013-12-31 | $4.86 Million | $-19.80 Million | -4.075x | -- |
About AC Immune Ltd
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines, and therapeutic and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. The company's SupraAntigen and Morphomer platforms are designed to generate biologics and small molecules, which selectively interact with misfolded proteins … Read more